Use of 111in-bleomycin for combining radiotherapy and chemotherapy on glioma-bearing mice

✍ Scribed by De-Yan Hou; Hans Hoch; Gerald S. Johnston; K. C. Tsou; Raymond J. Farkas; Elizabeth E. Miller

• Publisher: John Wiley and Sons
• Year: 1985
• Tongue: English
• Weight: 624 KB
• Volume: 29
• Category: Article
• ISSN: 0022-4790
• DOI: 10.1002/jso.2930290202

✦ Synopsis

Mice bearing transplanted glioma received 0.9% NaCl, 0.1 mg of BLM, or 200-250 pCi of "'In-BLM (0.1 mg BLM) daily for 5 days intraperitoneally. After therapy, tumor sizes were in the order NaCl > BLM > "'In-BLM. On the 11th day after the first injection, tumor size (m3) in the "'In-BLM group was 1,220; in the BLM group, it was 2,310 (P < .025). After intratumor injection of a total dose of 0.1 mg of BLM/gm tumor weight, or of 1 mCi/gm tumor weight of "'In-BLM (carried by 0.1 mg of BLM/gm tumor weight), the tumor size decreased in the "In-BLM group more than in the BLM group. On the 5th day after the 2nd dose therapy, the tumor size in the '"In-BLM group was 2,020; in the BLM group it was 4,220 (P < .05). Host weights for these two groups were similar. The necrotic area in the tumor was much greater in the "'In-BLM group than in the BLM group. These results suggest the use for radiotherapy and chemotherapy.